|
1
|
Bloom and Bennett. Mechanism of a reaction
in vitro associated with delayed-type hypersensitivity. Science.
153:80–82. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun HW, Bernhagen J, Bucala R and Lolis E:
Crystal structure at 2.6-A resolution of human macrophage migration
inhibitory factor. Proc Natl Acad Sci USA. 93:5191–5196. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leng L and Bucala R: Insight into the
biology of macrophage migration inhibitory factor (MIF) revealed by
the cloning of its cell surface receptor. Cell Res. 16:162–168.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosengren E, Bucala R, Aman P, Jacobsson
L, Odh G, Metz CN and Rorsman H: The immunoregulatory mediator
macrophage migration inhibitory factor (MIF) catalyzes a
tautomerization reaction. Mol Med. 2:143–149. 1996.PubMed/NCBI
|
|
5
|
Conroy H, Mawhinney L and Donnelly SC:
Inflammation and cancer: Macrophage migration inhibitory factor
(MIF)-the potential missing link. QJM. 103:831–836. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nishino T, Bernhagen J, Shiiki H, Calandra
T, Dohi K and Bucala R: Localization of macrophage migration
inhibitory factor (MIF) to secretory granules within the
corticotrophic and thyrotrophic cells of the pituitary gland. Mol
Med. 1:781–788. 1995.PubMed/NCBI
|
|
7
|
Roger T, Chanson AL, KnaupReymond M and
Calandra T: Macrophage migration inhibitory factor promotes innate
immune responses by suppressing glucocorticoid-induced expression
of mitogen-activated protein kinase phosphatase-1. Eur J Immunol.
35:3405–3413. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Santos LL and Morand EF: Macrophage
migration inhibitory factor: A key cytokine in RA, SLE and
atherosclerosis. Clin Chim Acta. 399:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sánchez-Zamora YI and Rodriguez-Sosa M:
The role of MIF in type 1 and type 2 diabetes mellitus. J Diabetes
Res. 2014:8045192014.PubMed/NCBI
|
|
10
|
Rendon BE, Roger T, Teneng I, Zhao M,
AlAbed Y, Calandra T and Mitchell RA: Regulation of human lung
adenocarcinoma cell migration and invasion by macrophage migration
inhibitory factor. J Biol Chem. 282:29910–29918. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He XX, Chen K, Yang J, Li XY, Gan HY, Liu
CY, Coleman TR and Al-Abed Y: Macrophage migration inhibitory
factor promotes colorectal cancer. Mol Med. 15:1–10. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Richard V, Kindt N, Decaestecker C, Gabius
HJ, Laurent G, Noël JC and Saussez S: Involvement of macrophage
migration inhibitory factor and its receptor (CD74) in human breast
cancer. Oncol Rep. 32:523–529. 2014.PubMed/NCBI
|
|
13
|
Guo P, Wang J, Liu J, Xia M, Li W and He
M: Macrophage immigration inhibitory factor promotes cell
proliferation and inhibits apoptosis of cervical adenocarcinoma.
Tumour Biol. 36:5095–5102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
MeyerSiegler KL, Iczkowski KA, Leng L,
Bucala R and Vera PL: Inhibition of macrophage migration inhibitory
factor or its receptor (CD74) attenuates growth and invasion of
DU-145 prostate cancer cells. J Immunol. 177:8730–8739. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kindt N, Preillon J, Kaltner H, Gabius HJ,
Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C,
Laurent G and Saussez S: Macrophage migration inhibitory factor in
head and neck squamous cell carcinoma: Clinical and experimental
studies. J Cancer Res Clin Oncol. 139:727–737. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kindt N, Lechien JR, Nonclercq D, Laurent
G and Saussez S: Involvement of CD74 in head and neck squamous cell
carcinomas. J Cancer Res Clin Oncol. 140:937–947. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dessein AF, Stechly L, Jonckheere N,
Dumont P, Monté D, Leteurtre E, Truant S, Pruvot FR, Figeac M,
Hebbar M, et al: Autocrine induction of invasive and metastatic
phenotypes by the MIF-CXCR4 axis in drug-resistant human colon
cancer cells. Cancer Res. 70:4644–4654. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He XX, Yang J, Ding YW, Liu W, Shen QY and
Xia HH: Increased epithelial and serum expression of macrophage
migration inhibitory factor (MIF) in gastric cancer: Potential role
of MIF in gastric carcinogenesis. Gut. 55:797–802. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tan L, Ye X, Zhou Y, Yu M, Fu Z, Chen R,
Zhuang B, Zeng B, Ye H, Gao W, et al: Macrophage migration
inhibitory factor is overexpressed in pancreatic cancer tissues and
impairs insulin secretion function of β-cell. J Transl Med.
12:922014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heise R, VetterKauczok CS, Skazik C, Czaja
K, Marquardt Y, Lue H, Merk HF, Bernhagen J and Baron JM:
Expression and function of macrophage migration inhibitory factor
in the pathogenesis of UV-induced cutaneous nonmelanoma skin
cancer. Photochem Photobiol. 88:1157–1164. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang XH, Jian WH, Wu ZF, Zhao J, Wang H,
Li W and Xia JT: Small interfering RNA (siRNA)-mediated knockdown
of macrophage migration inhibitory factor (MIF) suppressed cyclin
D1 expression and hepatocellular carcinoma cell proliferation.
Oncotarget. 5:5570–5580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mittelbronn M, Platten M, Zeiner P,
Dombrowski Y, Frank B, Zachskorn C, Harter PN, Weller M and
Wischhusen J: Macrophage migration inhibitory factor (MIF)
expression in human malignant gliomas contributes to immune escape
and tumour progression. Acta Neuropathol. 122:353–365. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao YM, Wang L, Dai Z, Wang DD, Hei ZY,
Zhang N, Fu XT, Wang XL, Zhang SC, Qin LX, et al: Validity of
plasma macrophage migration inhibitory factor for diagnosis and
prognosis of hepatocellular carcinoma. Int J Cancer. 129:2463–2472.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
DeSouza MB, Curioni OA, Kanda JL and De
Carvalho MB: Serum and salivary macrophage migration inhibitory
factor in patients with oral squamous cell carcinoma. Oncol Lett.
8:2267–2275. 2014.PubMed/NCBI
|
|
25
|
Cludts S, Decaestecker C, Johnson B,
Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ and
Saussez S: Increased expression of macrophage migration inhibitory
factor during progression to hypopharyngeal squamous cell
carcinoma. Anticancer Res. 30:3313–3319. 2010.PubMed/NCBI
|
|
26
|
Kindt N, Lechien J, Decaestecker C,
Rodriguez A, Chantrain G, Remmelink M, Laurent G, Gabius HJ and
Saussez S: Expression of macrophage migration-inhibitory factor is
correlated with progression in oral cavity carcinomas. Anticancer
Res. 32:4499–4505. 2012.PubMed/NCBI
|
|
27
|
Kamimura A, Kamachi M, Nishihira J, Ogura
S, Isobe H, DosakaAkita H, Ogata A, Shindoh M, Ohbuchi T and
Kawakami Y: Intracellular distribution of macrophage migration
inhibitory factor predicts the prognosis of patients with
adenocarcinoma of the lung. Cancer. 89:334–341. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tomiyasu M, Yoshino I, Suemitsu R, Okamoto
T and Sugimachi K: Quantification of macrophage migration
inhibitory factor mRNA expression in non-small cell lung cancer
tissues and its clinical significance. Clin Cancer Res.
8:3755–3760. 2002.PubMed/NCBI
|
|
29
|
Wang D, Luo L, Chen W, Chen LZ, Zeng WT,
Li W and Huang XH: Significance of the vascular endothelial growth
factor and the macrophage migration inhibitory factor in the
progression of hepatocellular carcinoma. Oncol Rep. 31:1199–1204.
2014.PubMed/NCBI
|
|
30
|
Chang KP, Lin SJ, Liu SC, Yi JS, Chien KY,
Chi LM, Kao HK, Liang Y, Lin YT, Chang YS and Yu JS:
Low-molecular-mass secretome profiling identifies HMGA2 and MIF as
prognostic biomarkers for oral cavity squamous cell carcinoma. Sci
Rep. 5:116892015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oliveira CS, de Bock CE, Molloy TJ,
Sadeqzadeh E, Geng XY, Hersey P, Zhang XD and Thorne RF: Macrophage
migration inhibitory factor engages PI3K/AKT signalling and is a
prognostic factor in metastatic melanoma. BMC Cancer. 14:6302014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Funamizu N, Hu C, Lacy C, Schetter A,
Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T and Yfantis HG:
Macrophage migration inhibitory factor induces epithelial to
mesenchymal transition, enhances tumor aggressiveness and predicts
clinical outcome in resected pancreatic ductal adenocarcinoma. Int
J Cancer. 132:785–794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xia HH, Yang Y, Chu KM, Gu Q, Zhang YY, He
H, Wong WM, Leung SY, Yuen ST, Yuen MF, et al: Serum macrophage
migration-inhibitory factor as a diagnostic and prognostic
biomarker for gastric cancer. Cancer. 115:5441–5449. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He LJ, Xie D, Hu PJ, Liao YJ, Deng HX,
Kung HF and Zhu SL: Macrophage migration inhibitory factor as a
potential prognostic factor in gastric cancer. World J
Gastroenterol. 21:9916–9926. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi X, Leng L, Wang T, Wang W, Du X, Li J,
McDonald C, Chen Z, Murphy JW, Lolis E, et al: CD44 is the
signaling component of the macrophage migration inhibitory
factor-CD74 receptor complex. Immunity. 25:595–606. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mitchell RA, Liao H, Chesney J,
FingerleRowson G, Baugh J, David J and Bucala R: Macrophage
migration inhibitory factor (MIF) sustains macrophage
proinflammatory function by inhibiting p53: Regulatory role in the
innate immune response. Proc Natl Acad Sci USA. 99:345–350. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li GQ, Xie J, Lei XY and Zhang L:
Macrophage migration inhibitory factor regulates proliferation of
gastric cancer cells via the PI3K/AKT pathway. World J
Gastroenterol. 15:5541–5548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jung H, Seong HA and Ha H: Critical role
of cysteine residue 81 of macrophage migration inhibitory factor
(MIF) in MIF-induced inhibition of p53 activity. J Biol Chem.
283:20383–20396. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hagemann T, Robinson SC, Thompson RG,
Charles K, Kulbe H and Balkwill FR: Ovarian cancer cell-derived
migration inhibitory factor enhances tumor growth, progression, and
angiogenesis. Mol Cancer Ther. 6:1993–2002. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Lu C, Xing G, Zhu Y and He F:
Macrophage migration inhibitory factor directly interacts with
hepatopoietin and regulates the proliferation of hepatoma cell. Exp
Cell Res. 300:379–387. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hu CT, Guo LL, Feng N, Zhang L, Zhou N, Ma
LL, Shen L, Tong GH, Yan QW, Zhu SJ, et al: MIF, secreted by human
hepatic sinusoidal endothelial cells, promotes chemotaxis and
outgrowth of colorectal cancer in liver prometastasis. Oncotarget.
6:22410–24423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baron N, Deuster O, Noelker C, Stüer C,
Strik H, Schaller C, Dodel R, Meyer B and Bacher M: Role of
macrophage migration inhibitory factor in primary glioblastoma
multiforme cells. J Neurosci Res. 89:711–717. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kindt N, Laurent G, Nonclercq D, Journé F,
Ghanem G, Duvillier H, Gabius HJ, Lechien J and Saussez S:
Pharmacological inhibition of macrophage migration inhibitory
factor interferes with the proliferation and invasiveness of
squamous carcinoma cells. Int J Oncol. 43:185–193. 2013.PubMed/NCBI
|
|
44
|
Ren Y, Chan HM, Fan J, Xie Y, Chen YX, Li
W, Jiang GP, Liu Q, Meinhardt A and Tam PK: Inhibition of tumor
growth and metastasis in vitro and in vivo by targeting macrophage
migration inhibitory factor in human neuroblastoma. Oncogene.
25:3501–3508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pei XJ, Wu TT, Li B, Tian XY, Li Z and
Yang QX: Increased expression of macrophage migration inhibitory
factor and DJ-1 contribute to cell invasion and metastasis of
nasopharyngeal carcinoma. Int J Med Sci. 11:106–115. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu H, Chen G, Zhang W, Zhu JY, Lin ZQ,
Gong ZC, Wang FQ, Jia J, Sun ZJ and Zhao YF: Overexpression of
macrophage migration inhibitory factor in adenoid cystic carcinoma:
Correlation with enhanced metastatic potential. J Cancer Res Clin
Oncol. 139:287–295. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Oda S, Oda T, Nishi K, Takabuchi S,
Wakamatsu T, Tanaka T, Adachi T, Fukuda K, Semenza GL and Hirota K:
Macrophage migration inhibitory factor activates hypoxia-inducible
factor in a p53-dependent manner. PLoS One. 3:e22152008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X,
Zhang Y and Wang S: Overexpression of macrophage migration
inhibitory factor induces angiogenesis in human breast cancer.
Cancer Lett. 261:147–157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Choudhary S, Hegde P, Pruitt JR, Sielecki
TM, Choudhary D, Scarpato K, Degraff DJ, Pilbeam CC and Taylor JA
III: Macrophage migratory inhibitory factor promotes bladder cancer
progression via increasing proliferation and angiogenesis.
Carcinogenesis. 34:2891–2899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
White ES, Flaherty KR, Carskadon S, Brant
A, Iannettoni MD, Yee J, Orringer MB and Arenberg DA: Macrophage
migration inhibitory factor and CXC chemokine expression in
non-small cell lung cancer: Role in angiogenesis and prognosis.
Clin Cancer Res. 9:853–860. 2003.PubMed/NCBI
|
|
52
|
Coleman AM, Rendon BE, Zhao M, Qian MW,
Bucala R, Xin D and Mitchell RA: Cooperative regulation of
non-small cell lung carcinoma angiogenic potential by macrophage
migration inhibitory factor and its homolog, D-dopachrome
tautomerase. J Immunol. 181:2330–2337. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hira E, Ono T, Dhar DK, ElAssal ON,
Hishikawa Y, Yamanoi A and Nagasue N: Overexpression of macrophage
migration inhibitory factor induces angiogenesis and deteriorates
prognosis after radical resection for hepatocellular carcinoma.
Cancer. 103:588–598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Girard E, Strathdee C, Trueblood E and
Quéva C: Macrophage migration inhibitory factor produced by the
tumour stroma but not by tumour cells regulates angiogenesis in the
B16-F10 melanoma model. Br J Cancer. 107:1498–1505. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fu H, Luo F, Yang L, Wu W and Liu X:
Hypoxia stimulates the expression of macrophage migration
inhibitory factor in human vascular smooth muscle cells via
HIF-1alpha dependent pathway. BMC Cell Biol. 11:662010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ioannou K, Cheng KF, Crichlow GV,
Birmpilis AI, Lolis EJ, Tsitsilonis OE and Al-Abed Y: ISO-66, a
novel inhibitor of macrophage migration, shows efficacy in melanoma
and colon cancer models. Int J Oncol. 45:1457–1468. 2014.PubMed/NCBI
|
|
57
|
Mawhinney L, Armstrong ME, O'Reilly C,
Bucala R, Leng L, Fingerle-Rowson G, Fayne D, Keane MP, Tynan A,
Maher L, et al: Macrophage migration inhibitory factor (MIF)
enzymatic activity and lung cancer. Mol Med. 20:729–735.
2015.PubMed/NCBI
|
|
58
|
Hussain F, Freissmuth M, Völkel D, Thiele
M, Douillard P, Antoine G, Thurner P, Ehrlich H, Schwarz HP,
Scheiflinger F and Kerschbaumer RJ: Human anti-macrophage migration
inhibitory factor antibodies inhibit growth of human prostate
cancer cells in vitro and in vivo. Mol Cancer Ther. 12:1223–1234.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Stein R, Mattes MJ, Cardillo TM, Hansen
HJ, Chang CH, Burton J, Govindan S and Goldenberg DM: CD74: A new
candidate target for the immunotherapy of B-cell neoplasms. Clin
Cancer Res. 13:5556s–5563s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Schulz R and Moll UM: Targeting the heat
shock protein 90: A rational way to inhibit macrophage migration
inhibitory factor function in cancer. Curr Opin Oncol. 26:108–113.
2014. View Article : Google Scholar : PubMed/NCBI
|
